Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome
Public ClinicalTrials.gov record NCT01100463. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Topical Cream (UTC) in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Study identification
- NCT ID
- NCT01100463
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Nanometics (d.b.a. PHD Biosciences)
- Industry
- Enrollment
- 18 participants
Conditions and interventions
Conditions
Interventions
- Cream Drug
- 0.1% Uracil Cream Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2010
- Primary completion
- Jul 31, 2011
- Completion
- Aug 31, 2011
- Last update posted
- Oct 7, 2019
2010 – 2011
United States locations
- U.S. sites
- 6
- U.S. states
- 5
- U.S. cities
- 6
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Bruno Cancer Center | Birmingham | Alabama | 35205 | — |
| Comprehensive Cancer Center | Palm Springs | California | 92262 | — |
| Research Institute of Deaconess Clinic | Evansville | Indiana | 47713 | — |
| Cancer Care Center | New Albany | Indiana | 47150 | — |
| Kansas City Cancer Centers | Overland Park | Kansas | 66210 | — |
| Signal Point Clinical Research Center | Middleton | Ohio | 45042 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01100463, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 7, 2019 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01100463 live on ClinicalTrials.gov.